Developing diagnostics and therapeutics for preeclampsia: targeting a novel placental specific sFlt-1 variant

开发先兆子痫的诊断和治疗方法：针对新型胎盘特异性 sFlt-1 变体

• 批准号: nhmrc : 1061977
• 负责人: Dr Kirsten Palmer
• 金额: $ 48.16万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/developing-diagnostics-therapeutics-1-variant/454948
• 关键词: Developing; diagnostics; therapeutics; preeclampsia; targeting

Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects of sFlt-1 as a strategy to develop drugs.

先兆子痫是一种可怕的妊娠疾病，在全球范围内造成数千名母亲和婴儿死亡。它是由一种名为sFlt-1的蛋白质从胎盘中泄漏出来并攻击母亲的器官引起的。最近，一种新的sflt-1亚型被发现是特定于胎盘。可能是子痫前期发病的关键致病毒素。我们将靶向这种胎盘特异性sFlt-1，以产生预测先兆子痫的诊断方法，并探索阻断sFlt-1毒性作用的新方法，作为开发药物的策略。